3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor

Table 1 [¹⁸F]FLT SUVbw Max and Volume Changes during drug treatment

Treatment Day	Baseline	Day 3	P vs baseline	Day 9	p vs baseline
SUV Max
Control	4.0 ± 2.4	5.1 ± 1.7	0.231	5.9 ± 1.9	0.0755
TMZ	4.1 ± 2.1	4.7 ± 3.1	0.521	6.1 ± 2.7	0.0418*
Palbociclib	6.0 ± 2.3	2.9 ± 2.2	0.042*	3.0 ± 1.0	0.0031*
Combo	6.1 ± 2.7	3.2 ± 1.7	0.011*	4.4 ± 2.2	0.0012*
Volume
Control	234 ± 69	349 ± 163	0.0032*	442 ± 197	0.0008*
TMZ	291 ± 117	392 ± 117	0.0037*	512 ± 245	0.0076*
Palbociclib	207 ± 126	229 ± 125	0.2951	256 ± 155	0.4083
Combo	279 ± 209	269 ± 179	0.4316	301 ± 220	0.4151

ISSN: 1479-5876